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Abstract 
Purpose: This study aims to evaluate the association between high sensitivity troponins (hsTn) and mitral annular 
plane systolic excursion (MAPSE) in patients undergoing cardiac magnetic resonance imaging (cMRI).
Methods: Patients undergoing cMRI were prospectively enrolled. Patients with right ventricular dysfunction (< 50%) 
were excluded. Blood samples for measurements of hsTn and amino‑terminal pro‑brain natriuretic peptide (NT‑
proBNP) were collected at the time of cMRI.
Results: 84 patients were included. Median left ventricular ejection fraction was 59% (IQR 51–64%). HsTn were cor‑
related inversely with MAPSE within multivariable linear regression models (hsTnI: Beta − 0.19; T − 1.96; p = 0.05; 
hsTnT: Beta − 0.26; T − 3.26; p = 0.002). HsTn increased significantly according to decreasing stages of impaired 
MAPSE (p < 0.003). HsTn discriminated patients with impaired MAPSE < 11 mm (hsTnT: AUC = 0.67; p = 0.008; hsTnI: 
AUC = 0.64; p = 0.03) and < 8 mm (hsTnT: AUC = 0.79; p = 0.0001; hsTnI: AUC = 0.75; p = 0.001) and were still 
significantly associated in multivariable logistic regression models with impaired MAPSE < 11 mm (hsTnT: OR = 4.71; 
p = 0.002; hsTnI: OR = 4.22; p = 0.009).
Conclusions: This study demonstrates that hsTn are able to reflect MAPSE being assessed by cMRI.
Keywords: Mitral annular plane systolic excursion, Natriuretic peptide, NT‑proBNP, High sensitivity troponin, troponin 
I, troponin T, Magnetic resonance imaging, MRI
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Background
Mitral annular plane systolic excursion (MAPSE) rep-
resents a central parameter of cardiac function being 
measured by cardiac magnetic resonance imaging (cMRI) 
[1]. MAPSE correlates with systolic longitudinal left 
ventricular (LV) contractility, and thus complements 
the assessment of LV ejection fraction (EF), which itself 
reflects circumferential LV contractility [2]. A reduc-
tion of MAPSE was shown to correlate with the presence 
of heart failure (HF) with preserved ejection fraction 
(HFpEF) [3]. Moreover, it was demonstrated that reduced 
MAPSE might reflect increased cardiac mortality and re-
hospitalization incidence in patients with HF, as well as 
in those with atrial fibrillation (AF) and after myocardial 
infarction [4].
Cardiac biomarkers, such as natriuretic peptides, reveal 
powerful diagnostic and prognostic values for the risk-
stratification of patients with HF [5]. Increased levels 
of amino-terminal pro-brain natriuretic peptide (NT-
proBNP) were shown to be associated with MAPSE as 
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being evaluated by transthoracic echocardiography [6]. 
Cardiac troponins (cTn) represent the major enzymes for 
myocardial contractility [7]. Recently developed sensitive 
troponin assays are characterized by an approximately 
hundredfold lower detection limit than conventional 
troponin assays [8]. Therefore, measurements of cardiac 
high sensitivity (hs) troponin I (TnI) and T (TnT) might 
bear the potential to diagnose a myocardial infarction 
much earlier compared to conventional troponin tests [9, 
10].
Within a community registry of atherosclerosis, ele-
vated hsTn were shown to reflect the presence of chronic 
heart failure (CHF) better than conventional tests due to 
its lower detection limit [11]. Furthermore, cardiac bio-
markers, such as NT-proBNP and hsTn, were shown to 
be associated with short- and long-term-prognosis in 
patients suffering from CHF with reduced and preserved 
ejection fraction (HFrEF and HFpEF) [7, 12, 13]. In addi-
tion, it was demonstrated that the concentration of hsTn 
related significantly to LVEF and LV end-diastolic pres-
sure measured by transthoracic echocardiography [14]. 
However, whether hsTn might be able to reflect MAPSE 
being assessed by cMRI is hardly investigated.
Therefore, this study aims to investigate whether con-
centrations of hsTn are able to reflect MAPSE being 
assessed by cMRI.
Methods
Study population
The “Cardiovascular Imaging and Biomarker Analy-
ses” (CIBER) study (clinicaltrials.gov identifier: NCT 
03074253) represents a clinically prospective, controlled 
and monocentric study conducted at the University Med-
ical Center Mannheim, Germany. The research adhered 
to the principals outlined in the Declaration of Helsinki 
and was approved by a regional ethics committee. Writ-
ten informed consent was obtained from all patients.
For the present study, patients undergoing cMRI dur-
ing routine clinical care were included consecutively to 
this study from February 2015 until June 2015 within an 
all-comers design. To perform valuable cMRI examina-
tion all patients had to be in a stable clinical condition 
without acute clinical symptoms, such as acute dysp-
nea or extensive peripheral edema. The indications for 
cMRI were not restricted to any specific cardiac disease 
entity. Exclusion criteria for cMRI accorded to com-
monly known exclusion criteria, such as claustrophobia 
and metal implants [1]. Specifically for the present study, 
patients with a reduced right ventricular function (RVF) 
below 50% were excluded.
All available clinical information of the study patients 
were documented, such as detailed findings of patients’ 
prior medical history, laboratory findings and medi-
cal therapies. Blood samples for biomarker measure-
ments were collected once within 24  h following cMRI 
examination.
Measurements of biomarkers
All expressed biomarkers were measured in the serum of 
patients’ blood. All samples were obtained by venipunc-
ture into serum  monovettes® and centrifuged at 2000 g 
for 10 min at 20  °C. The aliquoted samples were cooled 
down with liquid nitrogen before being stored at − 80 °C 
until analysis. The complete processing was conducted 
within two  hours after blood extraction. After thawing, 
the samples were mixed gently by inverting and centri-
fuged with 2500g for 10 min at 20 °C, respectively, 3000g 
for 30 min for hsTnI at 4 °C.
HsTnT was measured with the Troponin T hs STAT 
assay on a cobas e 602 analyzer (Roche Diagnostics, 
Mannheim, Germany). The limit of blank (LoB) for 
this assay was 3  ng/L and the limit of detection (LoD) 
was 5 ng/L as described in the instructions for use [15]. 
HsTnI was measured with the STAT High sensitivity 
Troponin-I assay on an Architect i1000 analyzer (Abbott, 
Wiesbaden, Germany). The LoB was 0.7–1.3  ng/L and 
the LoD was 1.1–1.9 ng/L for this assay as described in 
the instructions for use [16]. NT-proBNP was measured 
with the proBNP II STAT assay on a cobas e 602 analyzer 
(Roche Diagnostics, Mannheim, Germany). The LoD for 
this assay was 5 ng/L [17]. Creatinine was measured with 
the Creatinine Jaffe Gen.2 assay on a cobas c 702 analyzer 
(Roche Diagnostics, Mannheim, Germany).
cMRI acquisition
All studies were performed using a 1.5-T whole-body 
imaging system (Magnetom Avanto and Sonata, Siemens 
Medical Systems, Healthcare Sector, Erlangen, Germany) 
using a four-element (Sonata) or six-element (Avanto) 
phased-array body coil. Cine images were acquired using 
a retrospective electrocardiographic-gated, balanced seg-
mented steady-state free precession (trueFISP) sequence 
in three long-axis views (2-, 3-, and 4-chamber views) 
and in multiple short-axis views, covering the entire left 
ventricle from base to apex.
cMRI analysis
The cMRI image analysis was performed using the com-
mercially available computer software program  cvi42® 
(Circle Cardiovascular Imaging Inc., Calgary, Canada). 
MAPSE measurements were assessed on four-chamber 
view cine images. The distance between the basal septal 
mitral annulus (septal MAPSE), the basal lateral mitral 
annulus (lateral MAPSE) and a reference point outside 
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the left ventricular apex was measured in end-diastole 
and end-systole. The distance traveled by the septal and 
lateral annulus from end-diastole to end-systole was 
calculated as septal and lateral MAPSE by subtract-
ing the left ventricular end-systolic length from the left 
ventricular end-diastolic length as being described pre-
viously [18]. Average MAPSE was calculated as the aver-
age of septal and lateral MAPSE. Three sub-groups were 
set according to MAPSE: (MAPSE I: ≥ 11 mm, MAPSE 
II: ≥ 8 to < 11 mm, MAPSE III: < 8 mm).
Statistical analysis
For data with normal distribution, the Student’s t test 
was applied. Otherwise, Kruskal–Wallis test was used 
as non-parametric test. Deviations from a Gaussian 
distribution were tested by the Kolmogorov–Smirnov 
test. First, the clinical confounding factors influencing 
MAPSE in the total cohort were evaluated within mul-
tivariable linear regression model adjusted for hsTn and 
clinical parameters or comorbidities (coronary artery 
disease (CAD), valvular heart disease and AF). Second, 
MAPSE subgroups were set into MAPSE I:  ≥  11  mm; 
MAPSE II:  ≥  8 to <  11  mm; MAPSE III:  <  8  mm and 
the distribution of cMRI indices according to MAPSE 
subgroups was analyzed. Third, univariate correla-
tions between hsTn and cMRI parameters in all patients 
were analyzed using Spearman’s rank correlation for 
non-parametric data. In a fourth step, multivariable 
linear regression models adjusted for basic parameters 
(age, sex, creatinine) and clinical parameters or car-
diac comorbidities (CAD, valvular heart disease, AF, 
impaired left atrial function (LAF) < 45% and impaired 
MAPSE  <  8  mm) were performed for evaluating influ-
encing factors on hsTn in the present cohort. There-
after, receiver operating characteristic (ROC) curve 
analyses with area under the curves (AUC) were deter-
mined to evaluate whether biomarkers are able to dis-
criminate the presence of reduced MAPSE. ROC curves 
were compared by the method of Hanley et  al. [19]. In 
a last step, multivariable logistic regression models were 
developed to confirm the diagnostic value of hsTn for 
impaired MAPSE implicating pre-defined cutoffs, and 
these models were adjusted for basic parameters (age, 
sex, creatinine) and biomarkers (NTproBNP and hsTn). 
Multivariable linear or logistic regression analyses were 
performed with backward elimination. Parameters in 
multivariable models were included to these models as 
independent variables, when they revealed a known clin-
ical impact on or significant univariate correlations with 
the dependent variable. Data are presented as means 
with confidence intervals (CI) or medians with inter-
quartile ranges (IQR) (25th to 75th percentiles), depend-
ing on the distribution of the data. p values < 0.05 were 
considered as statistically significant. Statistical analyses 
were performed in all patients and in three sub-groups 
according to MAPSE: (MAPSE I:  ≥  11  mm; MAPSE 
II: ≥  8  mm −  <  11  mm; MAPSE III:  <  8  mm). Cutoffs 
of biomarkers were set at the group specific medians 
of each biomarker for the groups of reduced MAPSE. 
Power calculations were performed when multivariable 
regression models revealed lacking statistical signifi-
cance for the tested biomarkers. The calculations were 
performed with GraphPad Prism software (GraphPad 
Software Inc., San Diego, CA, USA) and SPSS software 
(IBM SPSS Statistics, IBM Corp., Armonk, NY, USA).
Results
Study population
A total of 84 patients were enrolled in the present 
study. Median age of the patients was 55  years (range 
18–85 years). Most patients were of male gender (n = 58, 
69%). Twenty-six patients suffered from compensated 
CHF (according to LVEF  <  55%) with only mild to 
moderate symptoms according to NYHA class I and II 
(n = 24, 92% of CHF patients). Thirteen patients suffered 
from AF, mostly paroxysmal AF (n =  8, 10%) (Table 1). 
Thirty-one patients suffered from valvular heart disease, 
mostly from mitral valve regurgitation (MR) (n  =  15, 
18%), followed by tricuspid (n = 10, 12%) and aortic valve 
regurgitation (n = 5, 6%). Thirteen patients suffered from 
mild MR (87% of all mitral valve regurgitation patients). 
Only one patient suffered from MR grade III and one 
patient from aortic valve stenosis grade III (data not 
shown). Twenty-six patients presented with CAD, and 
23% of these already underwent aorto-coronary bypass 
(ACVB) surgery (n  =  6). Seven patients suffered from 
chronic kidney disease, while no patient suffered from 
end-stage renal failure or was in need for hemodialysis. 
The median glomerular filtration rate (GFR) was 89 mL/
min (IQR 75–101  mL/min). Prior drug therapy is seen 
also in Table 1.
According to the extent of MAPSE, three subgroups 
were defined as follows: MAPSE I: MAPSE  ≥  11  mm 
(n  =  35, 42%), MAPSE II: MAPSE  ≥  8 to <  11  mm 
(n = 31, 37%), MAPSE III: MAPSE < 8 mm (n = 18, 21%).
The presence of CHF NYHA III (NYHA IV patients 
were not included in the present study), three-vessel 
CAD, grade III valvular heart disease, permanent AF 
and chronic kidney disease were comparable between 
the subgroups. Cardiac alterations in MAPSE subgroups 
were as follows: CHF NYHA III: MAPSE I: 0%, II: 50%, 
III: 50%; three-vessel CAD: MAPSE I: 31%, II: 54%, III: 
15%; grade III valvular heart disease: MAPSE I: 50%, II: 
50%, III: 0%; permanent AF: MAPSE I: 0%, II: 33%, III: 
67%; chronic kidney disease: MAPSE I: 14%, II: 43%, III: 
43%.
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Distribution of cardiac MRI indices according to MAPSE 
subgroups
Median LVEF was 59% (IQR 51–64%) in the total cohort 
(Additional file 1: Table S1). LVEF decreased significantly 
according to impaired subgroups of MAPSE (p = 0.007). 
Despite the exclusion of patients with RV dysfunction 
(RVF  <  50%), tricuspid annular plane systolic excursion 
(TAPSE) decreased significantly alongside with impaired 
MAPSE (p  =  0.0001) (Additional file  1: Table S1). Fur-
thermore, there were significant differences between 
between MAPSE subgroups regarding posterior wall 
thickness (PWT; p = 0.047) as well as LV stroke volume 
(LVSV; p  =  0.0001), RV end-diastolic volume (RVEDV, 
p = 0.0001), RV end-systolic volume (RVESV, p = 0.0001) 
and RVSV (p  =  0.0001) each being standardized with 
body surface area (BSA). No significant differences were 
observed for remodeling index, RVEF, septal wall thick-
ness (SWT), LVEDV/BSA and LVESV/BSA in the sub-
groups of MAPSE (p ≥ 0.05) (Additional file 1: Table S1).
Clinical confounding factors influencing MAPSE
Within multivariable linear regression models known 
clinical characteristics, cardiac comorbidities as well 
as hsTn were adjusted to evaluate their association on 
MAPSE within the present cohort. Adjusting for hsTn 
and the presence of CAD, valvular heart disease and AF, 
only hsTn and the presence of AF were associated signifi-
cantly with MAPSE (p < 0.05) (Table 2).
HsTn and NT‑proBNP in MAPSE sub‑groups
Figure  1a, b demonstrate significantly increasing hsTn 
values according to subgroups of decreased MAPSE 
(p  =  0.003 and p  =  0.0001). Due to the known left-
skewed distribution of hsTn [20], a severe reduction of 
MAPSE (MAPSE III) results in disproportionately high 
values of hsTn, and thus in a high 95% confidence inter-
val. Biomarker levels were as follows:
HsTnT: MAPSE I (median 5  ng/L, IQR 3–9  ng/L), 
MAPSE II (median 8  ng/L, IQR 3–11  ng/L), MAPSE 
III (median 12  ng/L, IQR 9–46  ng/L). HsTnI: MAPSE 
I (median 4.3  ng/L, IQR 3.1–6.4  ng/L); MAPSE II 
(median 7.0  ng/L, IQR 2.9–11.5  ng/L); MAPSE III 
(median 15.6  ng/L, IQR 8.1–62.8  ng/L). NT-proBNP 
(data not shown): MAPSE I (median 55.7  ng/L, IQR 
31.3–134.9  ng/L); MAPSE II (median 151.8  ng/L, IQR 
38.3–406.8  ng/L); MAPSE III (median 808.1  ng/L, IQR 
229.4–2285.8 ng/L) (p = 0.0001).
Correlations of hsTn with cMRI parameters and clinical 
characteristics
HsTn correlated significantly with MAPSE (hsTnI: 
r = − 0.33; p = 0.002; hsTnT: r = − 0.40; p = 0.0001), age 
Table 1 Baseline characteristics of study patients
ACE angiotensin converting enzyme, AT1 angiotensin 1, OAC oral anticoagulant, 
NOAC novel oral anticoagulant, CI confidence interval, IQR interquartile range
Characteristic Patients
(n = 84)
Age, mean (range; 95% CI) 55 (18–85; 52–59)
Gender, n (%)
 Male 58 (69)
 Female 26 (31)
Cardiovascular risk factors, n (%)
 Arterial hypertension 37 (44)
 Hypercholesterinemia 21 (25)
 Cardiac family history 15 (18)
 Smoking status 32 (38)
 Diabetes mellitus 11 (13)
 Adipositas 12 (14)
Laboratory parameters, median (IQR)
 Creatinine (mg/dL) 0.89 (0.78–1.04)
 GFR (mL/min) 89 (75–101)
Prior medical history, n (%)
 Chronic heart failure 26 (31)
  NYHA I 10 (38)
  NYHA II 14 (54)
  NYHA III 2 (8)
  NYHA IV 0 (0)
 Atrial fibrillation 13 (15)
  Paroxysmal 8 (10)
  Persistent 3 (4)
  Permanent 2 (2)
 Coronary artery disease 26 (31)
  1 vessel disease 10 (12)
  2 vessel disease 3 (4)
  3 vessel disease 13 (15)
 Past history of myocardial infarction 17 (20)
 Valvular heart disease 31 (37)
 Chronic kidney disease 7 (8)
 COPD 7 (8)
 Asthma 6 (7)
 Pneumonia 2 (2)
 Pulmonary hypertension 1 (1)
 Cancer 7 (8)
Medication, n (%)
 ACE‑inhibitor/AT1‑receptor antagonist 43 (51)
 Beta blocker 43 (51)
 Aldosterone antagonist 15 (18)
 Calcium antagonist 18 (21)
 Diuretics 45 (54)
 Acetylsalicylic acid 32 (38)
 Thienopyridines 9 (11)
 OAC/NOAC 14 (17)
 Statin 34 (40)
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(hsTnI: r = 0.45; p = 0.0001; hsTnT: r = 0.65; p = 0.0001) 
and NT-proBNP (hsTnI: r  =  0.64; p  =  0.0001; hsTnT: 
r = 0.69; p = 0.0001). Only hsTnT correlated significantly 
with creatinine (r =  0.24; p =  0.03), whereas hsTnI did 
not (r = 0.09; p = 0.4).
Additional file  2: Table S2 shows univariate correla-
tions of hsTn with cMRI parameters in all patients. HsTn 
did not reveal significant correlations with LV functional 
parameters (except for MAPSE) or TAPSE. In contrast, 
hsTn significantly correlated with posterior and septal 
wall thickness, remodeling index, as well as RVEF, RV 
end-diastolic and end-systolic volumes indexed to BSA, 
despite the exclusion of patients with RV dysfunction 
(RVF < 50%).
Afterwards, clinical characteristics and cardiac 
comorbidities including MAPSE were adjusted within 
multivariable linear regression models to evalu-
ate their association with hsTn. As shown in Table  3, 
MAPSE < 8 mm was correlated inversely with both hsTnI 
(left panel: Beta  =  −  0.19; T  =  −  1.96; p  =  0.05) and 
hsTnT (right panel: Beta = − 0.26; T = − 3.26; p = 0.002) 
even after adjusting with age, sex, creatinine, the pres-
ence of CAD, valvular heart disease, AF and impaired 
LAF < 45% (backward stepwise analysis).
hsTn discriminate reduced MAPSE
As analyzed by ROC curves, both hsTnT and hsTnI were 
able to discriminate significantly patients with impaired 
MAPSE  <  11  mm from all others (hsTnT: AUC =  0.67; 
95% CI 0.55–0.79; p  =  0.008; hsTnI: AUC  =  0.64; 95% 
CI 0.52–0.76; p  =  0.03) (Fig.  2a). Furthermore, both 
hsTnT and hsTnI were able to discriminate significantly 
patients with reduced MAPSE  <  8  mm from all oth-
ers (hsTnT: AUC = 0.79; 95% CI 0.69–0.89; p = 0.0001; 
hsTnI: AUC  =  0.75; 95% CI 0.62–0.89; p  =  0.001) 
(Fig. 2b). In contrast, AUCs of NT-proBNP were numeri-
cally greater than the AUCs of hsTn (NT-proBNP: 
MAPSE  <  11  mm: AUC  =  0.73; 95% CI 0.62–0.83; 
p = 0.001; MAPSE < 8 mm: AUC = 0.81; 95% CI 0.70–
0.93; p =  0.0001) but did not reveal a significant differ-
ence (p > 0.05) when comparing these ROC curves by the 
method of Hanley et al. [19] (Fig. 2a, b).
Table 2 Multivariable linear regression models for  evaluating associations between  MAPSE and  clinical characteristics 
and cardiac comorbidities
CAD coronary artery disease
Italic values indicate statistically significant p values (p < 0.05)
Beta T Adjusted
p value
Beta T Adjusted
p value
CAD − 0.06 − 0.51 0.62 − 0.10 − 0.92 0.36
Valvular heart diseases − 0.10 − 0.97 0.34 − 0.06 − 0.58 0.56
Atrial fibrillation − 0.23 − 2.18 0.03 − 0.27 − 2.65 0.01
Log hsTnT − 0.31 − 2.96 0.004 – – –
Log hsTnI – – – − 0.27 − 2.61 0.01
hs
Tn
T
(n
g/
L)
≥11 mm ≥8 - <11 mm              <8 mm
MAPSE I                MAPSE II               MAPSE III
(n=35)                    (n=31)                     (n=18)
p=0.0001
10
1
100   
hs
Tn
I(
ng
/L
)
≥11 mm ≥8 - <11 mm             <8 mm
MAPSE I               MAPSE II               MAPSE III
(n=35)                   (n=31)                    (n=18)
p=0.003
100
10
1
1000
a b
Fig. 1 Distribution of hsTnI (a) and hsTnT (b) serum concentrations according to subgroups of reduced MAPSE. Data are presented as medians with 
25th and 75th percentiles (boxes) and 5th and 95th percentiles (whiskers)
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hsTn reveal independent associations with impaired 
MAPSE
Finally, clinical characteristics, NT-proBNP and hsTn 
were adjusted within multivariable logistic regres-
sion models to evaluate their association with impaired 
MAPSE.
As shown in Table  4, patients with increased hsTnI 
levels  ≥  8.4  ng/L were 4.2 times more likely to suffer 
from MAPSE  <  11  mm (left panel: adjusted odds ratio 
(OR)  =  4.22; 95% CI 1.43–12.42; p  =  0.009), whereas 
patients with hsTnT values  ≥  9  ng/L were 4.7 times 
more likely to suffer from MAPSE < 11 mm (right panel: 
OR  =  4.71; 95% CI 1.78–12.51; p  =  0.002), even after 
adjustment with age, sex, creatinine and NT-proBNP 
(p > 0.05).
In contrast, patients with hsTnI levels  ≥  15.55  ng/L 
were not significantly associated with MAPSE  <  8  mm 
(p = 0.28), whereas patients with hsTnT values ≥ 12 ng/L 
were 3 times more likely to suffer from MAPSE < 8 mm 
(right panel: OR = 3.42; 95% CI 0.99–11.79; p = 0.05) in 
models being adjusted with age, sex, creatinine and NT-
proBNP (Table  5). Noteworthy, increased NT-proBNP 
levels were significantly associated with severely reduced 
MAPSE < 8 mm (p < 0.005). However, statistical power 
analysis in this subgroup revealed a valuable statistical 
power above 90% for hsTnI (difference between means 
of 0.441 (1.355–0.9136, mean log10 hsTnI MAPSE III—
mean log10 hsTnI MAPSE I +  II) p < 0.05). For hsTnT, 
the power was slightly lower with 70% to detect a differ-
ence between means of 0.021 with a significance level 
Table 3 Multivariable linear regression model for  evaluating associations between  hsTn and  clinical characteristics 
and cardiac comorbidities
CAD coronary artery disease, LAF left atrial function, MAPSE mitral annular plane systolic excursion
Italic values indicate statistically significant p values (p < 0.05)
Log hsTnI Log hsTnT
Beta T Adjusted
p value
Beta T Adjusted
p value
Age 0.11 1.02 0.31 0.26 3.05 0.003
Sex 0.04 0.41 0.69 0.04 0.54 0.59
Creatinine 0.27 2.82 0.006 0.40 4.96 0.0001
CAD 0.31 3.35 0.001 0.21 2.53 0.01
Valvular heart diseases − 0.15 − 1.59 0.12 − 0.07 − 0.89 0.38
Atrial fibrillation − 0.11 − 0.99 0.32 − 0.11 − 1.19 0.24
LAF (< 45%) − 0.23 − 2.36 0.02 − 0.11 − 1.33 0.19
MAPSE (< 8 mm) − 0.19 − 1.96 0.05 − 0.26 − 3.26 0.002
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Fig. 2 Receiver operating characteristic curves (ROC) revealing valuable discrimination of patients with reduced MAPSE of < 11 mm (a) 
and < 8 mm (b)
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(alpha) of 0.05 (two-tailed), while 50 patients in each 
group were needed to get a power of 80%.
Discussion
The present study demonstrates that levels of hsTn are 
able to reflect MAPSE being assessed by cMRI. Both 
hsTnI and hsTnT were inversely correlated with MAPSE 
within multivariable linear regression models and 
increased significantly according to the different stages 
of impaired MAPSE. HsTn discriminated both patients 
with impaired MAPSE < 11 and < 8 mm. In multivariable 
logistic regression models, hsTn were still significantly 
associated with impaired MAPSE  <  11  mm, even after 
adjustment for known influencing factors on hsTn release 
being known in clinical routine [20, 21]. NT-proBNP 
revealed comparable associations with reduced MAPSE.
There are several proteins participating in the regula-
tion of cardiac contraction such as the inhibitory protein 
TnI, the calcium binding protein TnC and the tropo-
myosin binding protein TnT, which together form the 
cTn complex. TnT is attached to the cardiac myofibrillar 
troponin–tropomyosin complex. TnC affinity for cal-
cium is reduced by TnI, whereby troponin–tropomyo-
sin interaction is inhibited [21]. Since both TnI and TnT 
are not expressed by damaged skeletal muscle, they are 
specific for cardiac injury [21–23]. cTn play an essen-
tial role in the diagnosis of acute myocardial infarction 
[10]. Furthermore, an association between elevated hsTn 
and an increased incidence rate of AF in patients with 
atherosclerosis was shown [24]. Besides, hsTnT corre-
lated significantly with reduced LVEF as well as elevated 
LV end-diastolic pressure in patients with stable CHF 
[14]. Additionally, hsTn were associated with short- and 
long-term prognosis in CHF patients [7, 12, 13]. Dinh 
et al. demonstrated an association of hsTnT and HFpEF, 
whereas the association is proportional to the severity 
of the disease [12]. Tsutamoto et  al. showed that hsTnI 
is an independent prognostic predictor in patients with 
CHF [13]. Furthermore, temporal increases of hsTnT 
were independently associated with incident coronary 
Table 4 Multivariable logistic regression models for  evaluating the diagnostic ability of  hsTn to  identify patients 
with reduced MAPSE of < 11 mm
CI confidence interval
Italic values indicate statistically significant p values (p < 0.05)
a An adjusted odds ratio of < 1 indicates an association of female gender with reduced MAPSE
hsTnI hsTnT
Adjusted  
odds ratio
95% CI Adjusted
p value
Adjusted  
odds ratio
95% CI Adjusted
p value
Age 0.97 0.94–1.00 0.048 0.99 0.95–1.02 0.42
Sexa 2.44 0.81–7.33 0.11 2.19 0.76–6.28 0.15
Creatinine 0.47 0.04–5.76 0.56 0.54 0.06–4.78 0.58
NT‑proBNP (≥ 285.2 ng/L) 1.81 0.45–7.30 0.40 2.48 0.66–9.34 0.18
hsTnI (≥ 8.4 ng/L) 4.22 1.43–12.42 0.009 – – –
hsTnT (≥ 9 ng/L) – – – 4.71 1.78–12.51 0.002
Table 5 Multivariable logistic regression models for  evaluating the diagnostic ability of  hsTn to  identify patients 
with reduced MAPSE of < 8 mm
CI confidence interval
Italic values indicate statistically significant p values (p < 0.05)
a An adjusted odds ratio of < 1 indicates an association of female gender with reduced MAPSE
hsTnI hsTnT
Adjusted  
odds ratio
95% CI Adjusted
p value
Adjusted  
odds ratio
95% CI Adjusted
p value
Age 0.98 0.94–1.02 0.36 0.99 0.95–1.04 0.71
Sexa 1.69 0.47–6.08 0.42 1.63 0.46–5.79 0.45
Creatinine 0.84 0.22–3.25 0.80 1.02 0.28–3.80 0.97
NT‑proBNP (≥ 808.0 ng/L) 10.00 2.87–34.84 0.0001 6.73 1.79–25.22 0.005
hsTnI (≥ 15.55 ng/L) 2.22 0.53–9.35 0.28 – – –
hsTnT (≥ 12 ng/L) – – – 3.42 0.99–11.79 0.05
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heart disease, death, and HF events [25]. Several studies 
demonstrated a correlation between elevated cTn levels 
and an increased risk of morbidity and mortality in both 
acute HF and CHF [21].
HF represents a preventable and treatable disease [26]. In 
early stages of HF, patients can present with asymptomatic 
structural or functional cardiac alterations (systolic or dias-
tolic LV dysfunction, reduced MAPSE), which are known 
as precursors of HF. It is of major importance to identify 
these precursors because they are related to a poor out-
come. Starting clinical follow-up as well as targeted medical 
therapy at the precursor stages of HF may reduce mortality 
in patients with asymptomatic compensated HF [27, 28].
Myocardial contraction during systole equates a com-
bination of longitudinal, radial and circumferential con-
tractions [2, 6] resulting in a combination of long axis 
shortening, radial wall thickening and circumferential 
shortening [29]. Whereas LVEF only reflects the com-
bined function of all components, but never specifi-
cally assesses longitudinal function, MAPSE represents 
the amount of displacement of the mitral annular plane 
towards the apex [4], and thus particularly reflects the 
contraction of longitudinal fibers, the corresponding lon-
gitudinal function [3, 4]. In diverse cardiac pathologies, 
transformations of longitudinal function already appear, 
when radial and circumferential functions are still unaf-
fected. Accordingly, longitudinal dysfunction assessed by 
MAPSE appears to be an early marker for cardiac pathol-
ogies [3, 4, 6, 29]. It was demonstrated that MAPSE was 
able to detect more subtle abnormalities of LV func-
tion (LVF) than LVEF [30, 31]. Wenzelburger et  al. 
showed that MAPSE could identify patients with HF and 
impaired LVF even when LVEF is still normal [3].
Longitudinal function plays an important role in car-
diac mechanics [29]. During LV systole, the mitral annu-
lus is pulled towards the apex as a result of long-fiber 
contraction, causing longitudinal shortening and a reduc-
tion of cavity size of the ventricle [2, 6, 32]. This longi-
tudinal shortening contributes 60% to the normal stroke 
volume [33, 34]. During early LV diastole, the position of 
the mitral annulus creates ventricular suction and thus 
ventricular filling [29, 34]. During advanced LV diastole, 
the mitral annulus moves back away from the apex, caus-
ing ventricular filling by moving around the column of 
blood stored in the left atrium [2, 6, 29, 34].
MAPSE was shown to correlate with global systolic LVF 
[4]. Furthermore, MAPSE correlated with several factors 
affecting LVF such as AF, CAD, myocardial infarction, 
dilated cardiomyopathy, HF and age [29, 30, 35–37]. Wil-
lenheimer et al. showed that MAPSE was strongly related 
to 1-year mortality [35]. Furthermore, Sveälv et al. found 
out that long-axis function had a significant influence on 
10-year survival in patients with CHF [38]. MAPSE was 
shown to be an independent predictor of major adverse 
cardiovascular events [29]. The main findings of Bergen-
zaun et al. were that MAPSE was an independent predic-
tor of 28-day mortality in critically ill patients with shock 
and systemic inflammation [39]. Furthermore, Rydberg 
et  al. suggested that reduced MAPSE, but not LVEF, is 
an independent predictor for the degree of aortic steno-
sis [40]. In several studies, a correlation between MAPSE 
and LVEF was demonstrated [2, 41]. Especially a value of 
MAPSE of less than 8 mm was associated with a reduced 
LVEF (< 50%) with a specificity of 82% and a sensitivity of 
98% [42].
The major advantage of the method assessing MAPSE 
is the simplicity of its measurement [43]. In the majority 
of patients, MAPSE can be assessed quite independent of 
imaging quality [4]. It requires no special analysis soft-
ware, can be performed rapidly and shows good inter- 
and intra-observer variability [18, 29]. In cMRI-derived 
MAPSE measurements, even better intra-and inter-
observer reproducibility compared to previous echocar-
diography studies were obtained [18].
To the best of our knowledge, the present study is 
the first, investigating the correlation between hsTnT, 
hsTnI and MAPSE being assessed by cMRI. Only one 
prior study suggested an association between hsTnT and 
MAPSE assessed via transthoracic echocardiographic 
examination in 47 critically ill patients with shock [39]. 
However, this analysis aims to combine the assessment 
of MAPSE by modern cMRI with the combination of two 
different pathophysiological families of blood biomark-
ers, the natriuretic peptide NT-proBNP and the ischemic 
biomarkers hsTnT and hsTnI.
Therefore, the diagnostic combination of hsTn and 
MAPSE being assessed by cMRI might detect poten-
tially early stages of LV dysfunction as being indicated 
by impaired MAPSE already, despite a still preserved 
or only slightly reduced LVEF and beyond clinical con-
founding factors known to influence hsTn release such 
as age, AF, renal failure. This sets out hsTn as even more 
sensitive biomarkers being of valuable benefit for realis-
tic clinical settings. Detecting LV dysfunction already at 
very early and compensated stages of CHF with only mild 
to moderate symptoms revealing only mild to moder-
ate reduction of LVEF and a still preserved LVSV turns 
MAPSE into a precursor of HF. Whether routine meas-
urements of hsTn either with or without cMRI imaging 
within standard of care in such patients might lead to a 
more close-meshed follow-up of these patients or might 
initiate or improve HF treatment at earlier stages needs 
to be addressed in upcoming larger prospective and ran-
domized controlled studies.
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Study limitations
Statistical power might have been only moderate in the 
subgroup of patients with MAPSE < 8 mm to specifically 
confirm/exclude an additional diagnostic value for hsTnT, 
as seen in the lack of statistical significance in multivari-
able regressions. Therefore, the present results need to be 
confirmed within larger patient cohorts including similar 
patients evaluating both hsTnT and hsTnI.
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